Traditional herbal medicine (THM) consists of a vast number of compounds that exert pharmacological effects throughout the body. Comprehensive phenotyping analysis using omics is essential for understanding the nature of THM in detail. We previously reported that the Japanese Kampo medicine maoto ameliorated flu-like symptoms in a rat infection model and dynamically changed plasma metabolites as indicated by metabolome analysis. The aim of this study was to apply wide-targeted plasma metabolomics with quantitative analysis of maoto compounds in a human clinical trial to evaluate the effect of maoto on plasma metabolites. Four healthy human subjects were recruited. Plasma samples were collected before and 0.25, 0.5, 1, 2, 4 and 8 h after maoto treatment. Wide-targeted metabolomics and quantitative analysis of the main chemical constituents of maoto were then performed. Plasma metabolome analysis revealed that maoto administration decreased essential amino acids including branched-chain amino acids (BCAAs) and increased various kinds of -3 fatty acids including eicosapentaenoic acid and docosahexaenoic acid, consistent with previous studies in rats. Fifteen of the major compounds in maoto were identified in the systemic circulation. Finally, the correlation between endogenous metabolites and maoto compounds in plasma was analyzed and the results indicated that the decrease in plasma BCAAs might be caused by ephedrines present in maoto. The present study demonstrated that plasma metabolomic studies of endogenous and exogenous metabolites are useful for elucidating the mechanism of action of THM.
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Introduction
Traditional herbal medicine (THM) is widely used around the world and particularly in Asia. THMs are prescribed for the treatment of various diseases including those in which conventional Western medical therapies produce unsatisfactory outcomes; thus, THMs might be able to address unmet medical needs. Although there are many reports describing benefits of THM in both clinical and preclinical studies, it is difficult to clarify the precise mechanism of action of THMs. Firstly, THMs contain a wide variety of constituents, many of which are bioactive [1, 2] ; however, the contributions of the individual components to the overall biological activity of THM remain unclear and it is presumed that compo-nents other than the primary bioactive constituents contribute to THM activity [3] . Secondly, the components of THM not only affect specific targets but also produce off-target effects in various sites in the body. Therefore, it is necessary to comprehensively investigate the constituents in THM and the phenotypes induced by THM administration. We have performed clinical pharmacokinetic studies of Japanese Kampo medicines and found various constituents to be absorbed into systemic blood [4] [5] [6] . However, the relationships among these bioavailable compounds and phenotypes have not been investigated.
In this study, we performed plasma metabolomics for phenotypic analysis of maoto, a pharmaceutical grade Kampo medicine. Metabolomics targets events downstream from other omics, such as genomics, transcriptomics, and proteomics, and is likely to provide valuable information that is more closely related to the phenotype. Therefore, plasma metabolomics may be useful for studying the effects of THM in the human body. Maoto was given orally at dose of 7.5 g. Blood samples were collected at 8 timepoints. Subjects had a meal 4 h after sampling (b) Wide-targeted metabolomic and quantitative analyses were performed using the plasma samples. To evaluate the relationship among the metabolites in plasma, correlation network analysis was performed using the results of both analyses.
Maoto (TSUMURA Maoto Extract Granules, TJ-27; Ma Huang Tang in Chinese) is prepared from a mixture of 4 component herbs, Armeniacae semen (AS), Glycyrrhizae radix (GR), Cinnamomi cortex (CC), and Ephedrae herba (EH). It is widely used to treat febrile symptoms of upper respiratory infections and influenza. Maoto was shown to have antipyretic activity in clinical studies [7, 8] and to decrease viral titer in a virus-infected mouse model [9] and cultured cell lines [10] . We recently performed plasma metabolome analysis following maoto administration in rats [11] . In that study, maoto was shown to ameliorate polyI:C-induced decrease in locomotor activity and body weight. Consistent with the relief of symptoms, maoto was also shown to decrease TNF-␣ and IL-1␤ and increase IL-10 in plasma. Additionally, maoto modulated the levels of plasma metabolites such as essential amino acids and inflammatory mediators. We hypothesize that maoto might ameliorate symptoms in part by inducing a wide range of changes in endogenous metabolism; however, plasma metabolomic data for maoto in humans are lacking.
In this study, maoto was administered in healthy male subjects, and blood samples were collected before and after maoto treatment (Fig. 1a) . Plasma samples were subjected to widetargeted metabolome analysis including quantitative analysis of blood-absorbed compounds derived from maoto (Fig. 1b) . We then explored relationships among the metabolites and maoto components to obtain information about the mechanism of action of maoto. The study demonstrated that plasma metabolomics and correlation analysis are useful methods for understanding the nature of THM.
Material and methods

Chemicals and reagents
Tsumura maoto extract granules for prescription (product code TJ-27, Tsumura & Co., lot number L03871, Tokyo, Japan) were used as the investigational product. The granules were manufactured according to GMP. Blood-absorbed components derived from maoto, namely, l-ephedrine hydrochloride, d-pseudoephedrine, dl-methylephedrine, and amygdalin were obtained from SigmaAldrich (St. Louis, MO). (E)-Cinnamic acid, liquiritin, liquiritigenin, glycyrrhizic acid, and glycyrrhetinic acid were from Wako Pure Chemical Industries (Osaka, Japan). 2-Methoxycinnamic acid and isoliquiritigenin were from Tokyo Chemical Industries (Tokyo, Japan). Prunasin was from Santa Cruz Biotechnology (Santa Cruz, CA). Isoliquiritin was from ChemFaces (Hubei, China). dlNorephedrine hydrochloride and methylephedrine N-oxide were from Tsumura & Co. with high purities for quantitative analysis.
Clinical trial
The trial was conducted at the Kochi Medical School in September 2016. The study protocol was approved by the Ethical Committee of Kochi Medical School. The trial was conducted in accordance with ethical norms prescribed in the Declaration of Helsinki and good clinical practice guidelines. All subjects read and signed the informed consent form prior to entering the study. The trial was registered in the University Hospital Medical Information Network (UMIN000023609; http://www.umin.ac.jp/). With respect to inclusion criteria, the studies included healthy Japanese adults between 20 and 45 years of age with a body mass index between 18 and 25 who were willing and able to comply with the study requirements. The exclusion criteria for this study included a history of significant liver, heart, or vascular disease, and consumption of supplements that contained any maoto compound, or any drug, within 3 days to 1 week before the first dose. Other standard exclusion criteria included relevant allergies and alcohol or nicotine use. The sample size was selected to allow characterization of the safety and pharmacokinetics of maoto compounds in healthy Japanese volunteers. Four male subjects (age, 22-29 years; height, 170.5-176.5 cm; weight, 53.8-73.9 kg; and BMI, 18.5-23.7 kg/m 2 ) were enrolled this study. The safety endpoint was evaluated in all subjects. This endpoint was defined on the basis of a physician's judgment after examination or observation that a serious adverse event had occurred. Adverse events included death, a lifethreatening event, an event requiring hospitalization for treatment or an extended stay in hospital, an event resulting in permanent or temporary disability or dysfunction, an event resulting in a congenital abnormality, or any other serious medical phenomenon. With respect to side effects, no specific conditions were defined, and all adverse events for which no causal relationship with the drug could be excluded were deemed to be side effects. During the 8-h period following maoto administration, the physician monitored the subject for subjective symptoms, objective findings, swelling, body temperature (axillary), blood pressure (sitting), and pulse (sitting). The physician also conducted a hematological examination which included measurement of each subject's red blood cell, leukocyte, and platelet count; hemoglobin level; hematocrit value; and prothrombin time. A biochemical examination was performed to determine total protein, blood urea nitrogen, creatinine, uric acid, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, (␥-glutamyltranspeptidase, albumin, total cholesterol, C-reactive protein, potassium, sodium, chlorine, and creatine phosphokinase to identify any abnormalities associated with the subject's condition prior to administration. All subjects fasted for 12 h before administration and 4 h after administration of the study drug. The subjects ate a controlled diet without maoto components from 3 days prior to the start of the study until the day of completion.
Maoto was given orally at a dose of 7.5 g, which is the daily dosage used in clinical practice. Blood samples were collected at 0 (pre-administration), 0.25, 0.5, 1, 2, 4, and 8 h after administration of maoto ( Fig. 1a) and were immediately centrifuged at 1700 × g and 4 • C for 15 min to obtain plasma. The plasma fractions were stored at −80 • C or below prior to GC-MS/MS and LC-MS/MS analyses.
Targeted metabolomics using GC-MS/MS
Plasma metabolome analysis using GC-MS/MS was performed according to a method described by Kitagawa et al. [30] . Briefly, 50 L of plasma was mixed with 260 L of a extraction solution (MeOH:H 2 O:CHCl 3 = 2.5:1:1, v/v/v) containing 10 L of 0.5 mg/mL 2-isopropylmalic acid (Sigma-Aldrich). Supernatant (150 L) was mixed with 140 L of distilled water. After mixing, 180 L of the supernatant was transferred to a clean tube and lyophilized. For oximation, 80 L of 20 mg/mL methoxyamine hydrochloride (Sigma-Aldrich) dissolved in pyridine was mixed with lyophilized sample. Samples were then shaken at 1200 rpm for 90 min at 30 • C. 40 L of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) (GL Science, Tokyo, Japan) was added for derivatization and the mixture was shaken at 1200 rpm for 30 min at 37 • C. The resultant supernatant was subjected to measurement by GC-MS/MS.
GC-MS/MS analysis was performed using a GCMS-TQ8040 (Shimadzu, Kyoto, Japan) with a fused silica capillary column (DB-5: inner diameter, 30 m × 0.25 m; film thickness, 1 m; Agilent Technologies, Santa Clara, CA). The analytical condition, chromatogram acquisition and waveform processing were summarized by Kitagawa et al. [30] . Typical chromatograms of the metabolites discussed in this study are shown in Supplementary Fig. 1 . The peak intensity of each quantified ion was calculated and normalized to that of 2-isopropylmalic acid, which was used as an internal standard. Further analysis was performed using normalized values.
Targeted metabolomics using LC-MS/MS
Plasma metabolome analysis using LC-MS/MS was performed according to the method described by Kitagawa et al. [30] . Briefly, 200 uL of plasma sample was mixed with 1 mL of methanol and internal standard mixture. The supernatant was diluted with 4 mL of 0.1% formic acid in water. The mixture was loaded onto a preconditioned solid-phase extraction cartridge (STRATA-X, 10 mg/1 mL, Phenomenex, Torrance, CA). The cartridge was washed with 1 mL each of 0.1% formic acid and 15% ethanol. Lipids were eluted with 250 L of 0.1% formic acid in methanol, and the eluent was evaporated using a vacuum evaporator (CC-105 and TU-1000, TOMY SEIKO CO., Tokyo, Japan) and reconstituted in 20 L of methanol. A 5-L aliquot of the sample was injected for analysis.
The LC-MS/MS system consisted of 2 LC-30AD pumps, a SIL-30AC auto-sampler, a CTO-20A column oven, a CBM-20A system controller, and a triple quadrupole mass spectrometer LCMS-8050 (Shimadzu). The analytical condition, chromatogram acquisition and waveform processing were summarized by Kitagawa et al. [30] . The typical chromatograms of the metabolites discussed in this study were shown in Supplementary Fig. 2 . The peak areas of each quantified ion were calculated and normalized to those of an internal standard mixture containing 0.5 ng/L each of the tetranor-PGEM-d6, TXB2-d4, PGE2-d4, PGD2-d4, LTC4-d5, LTB4-d4, 5-HETE-d8 and 15-HETE-d8, 0.25 ng/L of oleoylethanolamide (OEA)-d4, and 10 ng/L AA-d8 in methanol. Further analyses were performed using normalized values.
Quantitative analysis of the major components of maoto
Fifteen compounds, which were detected in rat plasma after administration of maoto or constituent herbs of maoto [11, 12] , were analyzed by SRM using LC-MS/MS. The plasma samples were pretreated according to the following methods prior to injection into the LC-MS/MS system.
For quantification of l-ephedrine, d-pseudoephedrine, lmethylephedrine, dl-norephedrine, and methylephedrine N-oxide, 100-L plasma samples were pretreated by liquid-liquid extraction using ethyl acetate. The total supernatant was collected, dried, and concentrated using a centrifugal evaporator. The dried residue was then dissolved in 60 L of the specific HPLC mobile phase used for each analytical method, and a 10-L aliquot was injected into the LC-MS/MS system. The recovery rate after addition of internal standard (IS) was ≥66.6% and the CV was ≤5.5%, and the recovery rate of analyte after addition of IS was ≥47.2% and the CV was ≤20.5%.
For quantification of amygdalin, prunasin, (E)-cinnamic acid, 2-methoxycinnamic acid, liquiritin, liquiritigenin, isoliquiritin, isoliquiritigenin, glycyrrhizic acid, and glycyrrhetinic acid, 100-L plasma samples were pretreated by deproteinization using methanol. The supernatant was collected, dried, and concentrated using a centrifugal evaporator. The dried residue was then dissolved in 60-80 L of the specific HPLC mobile phase used for the analytical method, and a 10-L aliquot was injected into the LC-MS/MS system. The recovery rate after addition of IS was ≥80.0% and the CV was ≤3.9%, and the recovery rate of analyte after addition of IS was ≥78.6% and the CV was ≤7.5%.
The LC/MS system consisted of a TripleQuad6500 (AB SCIEX, Tokyo, Japan) equipped with an Agilent 1290 system (Agilent Technologies). The analytical conditions were summarized by Kitagawa et al. [30] . Chromatogram acquisition, calibration curve generation, and plasma concentration calculations were performed using Analyst software Ver.1.6.2 (AB SCIEX). As an IS, niflumic acid (Sigma-Aldrich) and atropine sulfate monohydrate (Wako Pure Chemicals Industries) were selected based on consideration of the characteristic of the analytes, as these compounds were not detected in control plasma and did not overlap with other targets with respect to retention time and SRM transition. Typical SRM chromatograms for each of the analytical methods used for quantification of maoto components are presented in Supplementary  Fig. 3 . All components showed low or no detection in plasma before the administration of maoto. The linearity (correlation coefficient: r) of the calibration curves for quantification of plasma concentrations of maoto components was ≥0.99.
Processing and statistical analysis
The concentration of major components of maoto at each timepoint was calculated using standard curves. The value was designated as zero when the concentration was less than half of the quantification limit. Processing of metabolomics data was performed using Microsoft Excel software. Missing values in the raw data were replaced by half of the minimum positive value for each metabolite. In addition, metabolites with normalized area variation in pooled plasma samples >30% were removed from the detected metabolites since they were unstable [13] .
All data are expressed as mean ± SD or SE. Principal component analysis (PCA) was performed for the results of wide-targeted metabolomics using SIMCA 14 software (Umetrics, Sweden). The lipid mediator pathway was described using VANTED software (https://immersive-analytics.infotech.monash.edu/vanted/) [14] . One-way repeated ANOVA, Bonfferoni-corrected paired t-test, and Pearson correlation analysis were performed using MetaboAnalyst (http://metaboanalyst.ca/) [15] and Microsoft Excel software. The construction of the correlation network was performed using Cytoscape software (http://www.cytoscape.org/) [16] .
Results
Wide-targeted metabolomics
For wide-targeted metabolome analysis of plasma samples, hydrophilic metabolites (saccharides, amino acids and organic acids etc.) and lipid mediators were measured using GC-MS/MS 
and LC-MS/MS. A total 190 metabolites (149 and 41 in GC-MS/MS
and LC-MS/MS analyses, respectively) were detected in the plasma [30] . Principal component analysis (PCA) was performed using the normalized intensity of detected metabolites and all timepoints as variables ( Fig. 2a-d) . The results showed that the samples at 8 h after administration were clearly divided and the other samples were divided into groups by test subjects, not by sampling time (Fig. 2a) . However, when focusing on the change in individual cases, the changes up to 4 h were in the same direction from right to left on the PC1 axis (Fig. 2b) . Additionally, when the normalized intensity was transformed to a fold-change value (post-treatment per pretreatment), the samples were clearly separated by sampling time (Fig. 2c, d ). The separation of the samples at 8 h after administration was likely caused by meal ingestion.
The results for primary metabolites measured by GC-MS/MS were demonstrated by heat mapping (Fig. 3) . They consisted of annotated metabolites such as saccharides, amino acids, and metabolites related to the TCA cycle and fatty acid metabolism. Most of the amino acids, especially essential amino acids including branched-chain amino acids (BCAAs), were decreased 1 h after administration of maoto. Conversely, branched-chain ␣-keto acids (BCKAs), which are the oxidation products of BCAA, were increased immediately after administration. Some free fatty acids (FFAs), glycerol, and acetoacetic acid showed similar kinetics, i.e., decreasing immediately after administration and increasing 2 h after administration. Lactose was dramatically increased immediately after administration, which was expected since it is an additive agent in maoto.
The results of lipid mediator analysis were demonstrated by pathway mapping (Fig. 4a ). -3 Fatty acids like docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and their metabolites were increased immediately after administration of maoto. Regarding -6 fatty acids, plasma levels of arachidonic acid (AA) and its metabolites were also increased. Since the subjects did not suffer from any diseases associated with inflammation, the increase of AA did not lead to up-regulation of pro-inflammatory mediators like prostaglandins and leukotrienes. The kinetic profiles of DHA, EPA, and AA showed a similar biphasic pattern, increasing immediately and at 1 h after administration (Fig. 4b) . 
Quantitative analysis of the major components of maoto
We performed quantitative analysis of 15 compounds derived from maoto [30] . All of the targeted-compounds were detected in the plasma post-administration. Plasma concentrations of each compound were diverse, and some compounds that showed higher concentrations were at levels of approximately 100 ng/mL or greater (Fig. 5) . For instance, prunasin showed the highest concentration, with a maximum concentration of 259 ng/mL, followed by l-ephedrine (91.2 ng/mL), and (E)-cinnamic acid (84.4 ng/mL). Additionally, the blood-absorbed compounds also showed diverse kinetic profiles (Fig. 5 ). For instance, (E)-cinnamic acid appeared very rapidly in plasma, and the concentration of (E)-cinnamic acid reached the highest point at 0.25 h after administration. However, the concentrations of glycyrrhetinic acid and liquiritigenin peaked at 8 h after administration.
Correlation network analysis
Pearson correlation analysis was performed to explore relationships among the plasma metabolites (plasma concentration of maoto components and amount of targeted metabolites) changed by maoto administration. A total 24 samples (4 subjects, 6 sampling points [Pre, 0.25, 0.5, 1, 2, 4 h]) were used. Samples at 8 h after administration were excluded to avoid the effect of meal ingestion. A total of 74 metabolites that were significantly changed by maoto administration (Supplementary Table 1) , and 15 maoto components (Fig. 5) , were used as variables. When the correlation network was constructed using a Pearson correlation coefficient greater than 0.8 (|R| > 0.8), several communities could be found (Fig. 6 ). Among them, ephedrines were negatively correlated with BCAAs (Cluster A in Fig. 6 ). BCAAs were also positively correlated with essential amino acids, and hippuric acid was well-correlated with maoto components (Cluster B in Fig. 6 ). TCA cycle metabolites were in the same cluster (Cluster C in Fig. 6 ). Free fatty acids including AA, linoleic acid metabolites (DiHOMEs and HODEs), and OEA belonged to the same community (Cluster D in Fig. 6 ). Although EPA and DHA showed a strong correlation, they were not highly correlated with any other metabolites.
Discussion
The primary objective of this study was to apply plasma widetargeted metabolome analysis in a human clinical study to evaluate the effect of maoto on plasma metabolites. Since THMs were assumed to exert their activity by affecting various sites in the body, it was reasoned that comprehensive plasma metabolome analysis could provide essential information for understanding the nature of THM. The assessment of the utility of plasma metabolome analysis in this study had some limitations. The sample size was small, and a placebo or no-treatment group was not included in the study. However, PCA using the results of plasma wide-targeted metabolomics The results of mediator analysis were mapped onto -3 and -6 fatty acid pathways. The visualization of the heat map is the same as that shown in Fig. 3 . Mediators shown by gray circles represent target mediators that were below the limit of detection. Black dots represent mediators that were not targeted in our analysis. (b) Changes in EPA, DHA, and AA after administration of maoto. Each graph shows individual results. These mediators were increased twofold in 3 of 4 subjects. AA, arachidonic acid; AEA, arachidonoyl ethanolamide; ALA, ␣-linolenic acid; DGLA, dihomo-␥-linolenic acid; DHA, docosahexaenoic acid; DHET, di-hydroxy-eicosatrienoic acid; DiHETE, di-hydroxy-eicosatetraenoic acids; DPA, docosapentaenoic acid; EDA, eicosadienoic acid; EET, epoxy-eicosatrienoic acid; EPA, eicosapentaenoic acid; GLA, ␥-linolenic acid; HDoHEs, hydroxyl-docosahexaenoic acids; HEDE, hydroxy-eicosadienoic acid; HEPE, hydroxy-eicosapentaenoic acids; HETE, hydroxy-eicosatetraenoic acids; HODE, hydroxy-octadecadienoic acid; HOTrE, hydroxy-octadecatrienoic acid; HpEPE, hydroperoxy eicosapentaenoic acid; HpETE, hydroperoxy-eicosatetraenoic acid; KEDE, oxo-eicosadienoic acid; KETE, oxo-eicosatetraenoic acid; KODE, oxo-octadecadienoic acid; LA, linoleic acid; LT, leukotriene; PG, prostagrandine; TX, thromboxane. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
showed a consistent effect of maoto administration in all 4 subjects (Fig. 2) . We previously evaluated the effect of maoto on plasma metabolites in rats by comparing a group treated with maoto versus an untreated group [11] . The results demonstrated that administration of maoto resulted in a decrease in plasma BCAA levels and an increase in plasma EPA and DHA levels, which were effects that were also observed in the human study. Since the phenomena observed in the rat study would be independent of circadian variation, the results are relevant to the interpretation of the results of the present study in humans. In addition, the plasma concentration of the major compounds in maoto were useful in the correlation analysis to explain the role of maoto administration in causing the observed phenomena, since the kinetics of maoto compounds in plasma would be independent of circadian variation.
Plasma wide-targeted metabolomics showed that administration of maoto decreased essential amino acids including BCAAs, and increased EPA, DHA, and AA. Our previous study demonstrated decreased essential amino acids including BCAAs, and increased EPA and DHA, in the plasma of rats treated with maoto relative to control rats treated with water ( Supplementary Fig. 4) [11] . Addi- tionally, it has been reported that the levels of EPA, DHA, and AA in human plasma are highest at midmorning to noon, after which they decline [17] . The increase of these mediators following maoto administration occurred in the midmorning. Therefore, it appears that the effects of maoto demonstrated in this study were caused by maoto administration rather than circadian variation.
EPA, DHA and AA are primary substrates of -3 and -6 fatty acids. -3 Fatty acids suppress lipopolysaccharide-stimulated TNF␣ in macrophages via NF-B inhibition [18] , and inflammatory mediators, such as prostaglandins and leukotrienes, by competing for metabolic enzymes with AA [19] . Therefore, the increase in -3 fatty acids caused by maoto administration appears to be partly responsible for the drug's anti-inflammatory activity, as indicated in a previous study using a rat model [11] . Regarding the plasma kinetics of these mediators, they were transiently increased after administration and again slowly 1 h after administration (Fig. 4b) . Some of the mediators located downstream of EPA, DHA, and AA showed the same kinetics. Since the mediators were changed uniformly, their increase did not seem to be caused by specific metabolic enzymes such as cytochrome p450, cyclooxygenase, and lipoxygenase. Therefore, it is likely that the effect of maoto on lipid mediators would not be caused by modulation of metabolic enzymes, but rather by the supply of substrates. It is possible that the origin of EPA, DHA, and AA would be the side chains of phospholipids (Lands cycle) [20] or maoto components. Further analysis including lipidomics for plasma and maoto are needed to elucidate the mechanism of induction of these lipid mediators by maoto administration.
Regarding the decrease of plasma amino acids, it was demonstrated in the correlation network analysis that the plasma concentration of ephedrine and its analogs strongly correlated with the content of BCAAs in plasma, and BCAAs were also correlated with essential amino acids (Cluster A in Fig. 6 ). Oral administration of ephedrine has been reported to increase fasting insulin levels [21] . Insulin stimulates amino acid uptake as well as uptake of glucose and fatty acids [22, 23] . Therefore, the decrease of amino acids shown in this study would likely be caused by insulin secretion induced by ephedrines. The reason for the acute increase of BCKAs, which are degradation products of BCAAs, remains to be determined. FFAs, glycerol, and acetoacetic acid were decreased immediately after administration and subsequently increased. Many FFAs are reported to be decreased in the morning and then subsequently become stable [17] ; therefore, the decrease of FFAs observed in this study may be due to circadian variation. However, the increase at 2 h after administration is more likely due to maoto.
Quantitative analysis of the chemical constituents of maoto showed results similar to those in a previous rat study [11] . The detected compounds showed a wide range of concentrations and kinetics in plasma. The difference in pharmacokinetic profiles would likely depend on the amounts of the compounds in the formulation, the physical properties of the compounds, and their metabolism. l-Ephedrine is a primary constituent in EH, and the plasma concentration was relatively high. Although it has been reported that the plasma-time profile of l-ephedrine is regulated by several factors, including metabolism [24] , its plasma concentrations and that of related compounds (d-pseudoephedrine, dl-norephedrine, l-methylephedrine, methylephedrine N-oxide) showed similar kinetics after the administration of maoto. Although amygdalin (D-mandelonitrile ˇ-D-gentiobioside) is a primary and abundant constituent of AS [25] , the plasma concentration was low; i.e., 3.67 ng/mL at 1 h after maoto administration. Amygdalin is hydrolyzed to prunasin (D-mandelontrile ˇ-Dglucoside) in the small intestine, and subsequently transferred to the intestinal wall [26, 27] . The plasma concentration of prunasin was much higher than that of amygdalin; therefore, it is likely that most of the amygdalin was converted to prunasin in the small intestine after maoto administration. Glycyrrhetinic acid and liquiritigenin were detected at a later stage, which was consistent with the results of other pharmacokinetic studies of Kampo medicines containing GR [4] .
Correlation network analysis demonstrated the relationships among endogenous metabolites and maoto components, such as the correlation among ephedrines, BCAAs, and essential amino acids mentioned above. Several correlations were in accordance with the known metabolic pathway. Hippuric acid was wellcorrelated with maoto components (Cluster D in Fig. 6 ). Hippuric acid has been reported to be a metabolite of cinnamic acid [28] , which is consistent with the correlation observed in the present study. Regarding the other correlation that overlapped the metabolic pathway, one cluster contained TCA cycle metabolites (Cluster C in Fig. 6 ), and another cluster consisted of FFAs, especially linoleic acid metabolites (Cluster D in Fig. 6 ). Although it is reasonable that these correlations formed clusters, it is difficult to distinguish whether the clusters were a result of maoto administration or circadian variation in the case of clusters that consisted of endogenous metabolites. On the contrary, plasma concentrations of maoto compounds were expected to be independent of circadian variation. Therefore, it can be assumed that the clusters including maoto components, such as ephedrines, BCAA cluster, and hippuric acid cluster, would be caused by maoto administration. Another limitation of the correlation analysis in this study was that it was performed using 24 samples, derived from 4 subjects at 6 sampling points. Therefore, the correlation would reflect time-dependent changes rather than a difference between subjects.
Since the efficacy of Kampo medicine is variable among patients [29] and the individual difference in plasma metabolome profiles was large (Fig. 2) , it is expected that a correlation analysis using more subjects in the same sampling timeframe would enable identification of a responder biomarker and provide information about the mechanism of action of THMs.
Conclusions
In conclusion, the present study revealed that maoto influenced various plasma metabolites and that some changes, such as those of BCAAs and -3 fatty acids, represent species-independent phenotypes. Additionally, the decrease in BCAAs induced by maoto administration might be caused by ephedrines in EH, according to the correlation network analysis. The present study demonstrated that metabolomics and correlation analysis were valuable for elucidating the mechanism of action of THMs.
